Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06291337 · ClinicalTrials.gov registry record · NA
Ibuprofen Inhibits Human Sweet Taste
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT06291337 is a NA study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 32 participants.
The verdict
NCT06291337, a NA study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The sweet taste receptor, TAS1R2-TAS1R3, is expressed both orally, where it signals sweet taste, and extraorally in the intestine and pancreas, where it may affect glucose absorption and metabolism. Recently, ibuprofen and naproxen have been identified to inhibit human T1R3 when heterologously expressed in cells. In the present study, the initial objective was to determine if ibuprofen and naproxen inhibit interactions of sugars with human sweet taste receptor under normal, physiological conditions. Ten healthy participants were asked to rate sweetness intensity for a range of sweet stimuli (sucrose, fructose, sucralose) after a prerinse of ibuprofen, naproxen or water. Both ibuprofen and naproxen inhibited sweet taste intensity in a dose-dependent manner. In association studies, ibuprofen use has been linked to preserved metabolic function, as its use is correlated with lower rates of Alzheimer's disease, diabetes and colon cancer. Here the investigators present a potential novel pathway for systemic ibuprofen to impact these metabolic diseases.
Interventions
- DRUG Inhibition of Sweet Taste by Ibuprofen Oral Rinses
- DRUG Inhibition of Sweet Taste by Naproxen Oral Rinses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2023-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06291337
The ClinicalTrials.gov registry entry for NCT06291337 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Inhibition of Sweet Taste by Ibuprofen Oral Rinses is the first listed.
NCT06291337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06291337 about?
NCT06291337 is a clinical study titled "Ibuprofen Inhibits Human Sweet Taste". The sweet taste receptor, TAS1R2-TAS1R3, is expressed both orally, where it signals sweet taste, and extraorally in the intestine and pancreas, where it may affect glucose absorption and metabolism. Recently, ibuprofen and naproxen have been identified to inhibit human T1R3 when heterologously expre...
What is the current status of trial NCT06291337?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2020-06-01. Estimated completion is 2023-09-30.
What interventions are being tested in trial NCT06291337?
The interventions under investigation include: Inhibition of Sweet Taste by Ibuprofen Oral Rinses (DRUG), Inhibition of Sweet Taste by Naproxen Oral Rinses (DRUG).
Who is sponsoring clinical trial NCT06291337?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.